On average pain decreased 29 points and function improved 43 points. Lauweryns found intra-cage bridging bone occurred in 98 percent of patients treated with i-FACTOR biologic bone graft versus 59 percent of patients treated with local autograft. Lauweryns studied 40 patients undergoing PLIF surgery and assessed their progress using radiographs, CT scans, the Visual Analog Scale (VAS), and Oswestry Disability Index (ODI).Īfter six months, Dr. I-FACTOR™ biologic bone graft features synthetic small peptide (P-15) technology that supports bone growth through cell attachment and osteoblast differentiation.

'This study suggests that i-FACTOR biologic bone graft may have equal or greater efficacy at six and 12 months following PLIF procedures, and pain and functional improvements exceeded success criteria.' 'There are alternatives to autograft and its associated risks, some of which may be more effective in the formation of bridging bone,' said Dr.

Researchers led by Dr. Philippe Lauweryns, orthopedic surgeon at Sint-Trudo Ziekenhuis hospital in Belgium, concluded i-FACTOR™ biologic bone graft may be a viable alternative to autograft in PLIF procedures. During the study, bridging bone inside hollow disc cages in the spine developed earlier with the use of i-FACTOR™ biologic bone graft when compared to autograft, while average pain decreased and function improved. Cerapedics, a privately-held orthobiologics company, today announced results of a study examining the efficacy and safety of the company's i-FACTOR™ biologic bone graft in posterior lumbar interbody fusion (PLIF), a common spine surgery to relieve chronic back pain.

Innovative ifactor